Characteristics and outcomes according to axSpA sub-diagnosis
| Nr-axSpA (N=362) | AS (N=622) | P | |
|---|---|---|---|
| Baseline demographics | |||
| Age, years | 38 (30–46) | 42 (33–52) | <0.001 |
| Male sex, n (%) | 183 (50) | 455 (73) | <0.0001 |
| HLAB27 positive, n (%) | 253 (70) | 395 (83) | 0.005 |
| Disease duration, years | 1 (0–3) | 3 (1–12) | <0.0001 |
| Baseline disease activity | |||
| CRP, mg/l | 7 (3–17) | 11 (5–22) | <0.0001 |
| BASDAI, mm | 64 (54–77) | 59 (46–71) | <0.0001 |
| BASFI, mm | 52 (33–69) | 49 (34–67) | 0.7 |
| BASMI | 20 (10–40) | 40 (20–50) | <0.0001 |
| VAS global, mm | 76 (62–88) | 68 (50–80) | <0.0001 |
| Crude outcomes | |||
| BASDAI50%/20mm response, % | 46 | 48 | 0.9 |
| Adherence, median (95%CI), years | 1.59 (1.15–2.02) | 3.67 (2.86–4.49) | <0.0001 |